Abstract

1-a. In a multimeric protein, two polypeptide chains can be connected to each other by such connector.

IPC Classes  ?

• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• C07K 14/595 - GastrinsCholecystokinins [CCK]
• C07K 14/735 - Fc receptors
• C07K 7/08 - Linear peptides containing only normal peptide links having 12 to 20 amino acids
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• C07K 16/00 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies
• C07K 14/705 - ReceptorsCell surface antigensCell surface determinants
• A61K 39/39 - Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants

Abstract

The invention provides for an immunogenic composition comprising a. a directed adjuvant comprising at least an anti-CD32 moiety linked to a TLR9 ligand and a first peptidic alpha-helix; and b. an immunogen comprising an extracellular Her2/neu domain that is linked to a second peptidic alpha-helix coiled to the first alpha-helix; The invention further provides a kit for producing such immunogenic composition, a vaccine comprising such immunogenic composition and its medical use, such as for treating Her2/neu positive tumor diseases.

IPC Classes  ?

• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 39/39 - Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
• A61P 35/00 - Antineoplastic agents

Abstract

A connector of a helical coiled coil-type structure connecting a first and a second molecule, wherein the first molecule comprises a peptidic first alpha-helix and the second molecule comprises a peptidic second alpha-helix, which second alpha-helix is coiled to the first alpha-helix; wherein the first alpha-helix comprises i) a C-terminal region consisting of a repeat of an amino acid motif a-x and the C-terminal motif a-x1-x2; or ii) an N-terminal region consisting of a repeat of an amino acid motif x1-a and the N-terminal motif x2-x1-a; wherein a is a motif sequence of 4-8 amino acids; x1 is Lysine; and x2 is an extension of the motif, wherein the extension consists of 1-10 amino acids, and wherein the extension does not comprise more than 4 consecutive amino acids incorporated in said motif a-x1 or x1-a; and a multimeric protein comprising at least two polypeptide chains connected to each other by such connector, wherein a first polypeptide chain incorporates the first alpha-helix, and the second first polypeptide chain incorporates the second alpha-helix; and wherein the first and second polypeptide chains are connected by the helical coiled-coil type structure of the first and second alpha-helices.

IPC Classes  ?

• C07K 7/08 - Linear peptides containing only normal peptide links having 12 to 20 amino acids
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• C07K 14/595 - GastrinsCholecystokinins [CCK]
• C07K 14/705 - ReceptorsCell surface antigensCell surface determinants
• C07K 14/735 - Fc receptors
• C07K 16/00 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies

Abstract

The invention provides for an immunogenic composition comprising a. a directed adjuvant comprising at least an anti-CD32 moiety linked to a TLR9 ligand and a first peptidic alpha-helix; and b. an immunogen comprising an extracellular Her2/neu domain that is linked to a second peptidic alpha-helix coiled to the first alpha-helix; The invention further provides a kit for producing such immunogenic composition, a vaccine comprising such immunogenic composition and its medical use, such as for treating Her2/neu positive tumor diseases.

IPC Classes  ?

• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 39/39 - Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants